Drug Profile


Alternative Names: BIA-91067; Ongentys; ONO-2370

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator Bial
  • Developer BIAL; Ono Pharmaceutical
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 17 Oct 2016 Launched for Parkinson's disease (Adjunctive treatment) in United Kingdom (PO)
  • 17 Oct 2016 Updated efficacy data from the phase III BIPARK I and BIPARK II trial in Parkinson's disease released by Bial
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top